Xcopri, Ontozry(cenobamate)
Ontozry, Xcopri (cenobamate) is a small molecule pharmaceutical. Cenobamate was first approved as Xcopri on 2020-03-10. It is used to treat partial epilepsies in the USA. It has been approved in Europe to treat epilepsy. It is known to target gamma-aminobutyric acid receptor subunit alpha-4 and gamma-aminobutyric acid receptor subunit alpha-6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Xcopri
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cenobamate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XCOPRI | SK Life Science | N-212839 RX | 2020-03-10 | 6 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xcopri | New Drug Application | 2024-08-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| epilepsy | EFO_0000474 | D004827 | G40.9 |
| partial epilepsies | EFO_0004263 | D004828 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CENOBAMATE, XCOPRI, SK LIFE | |||
| 2025-03-10 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Seizures | D012640 | HP_0002069 | G40.4 | 1 | 3 | 6 | 1 | 3 | 14 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | 2 | 2 | 1 | 5 | 11 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Partial epilepsies | D004828 | EFO_0004263 | — | 1 | 3 | 2 | — | 2 | 8 |
| Generalized epilepsy | D004829 | — | — | — | — | 3 | — | — | 3 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Nervous system diseases | D009422 | — | G00-G99 | 1 | — | — | — | 1 | 2 |
| Drug misuse | D000076064 | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cenobamate |
| INN | cenobamate |
| Description | Cenobamate, sold under the brand names Xcopri (US) and Ontozry (EU), is a medication used for the treatment of partial-onset seizures, a kind of epilepsy, in adults. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | tranquilizers/antiepileptics (propanediol and pentanediol groups) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl |
Identifiers
| PDB | — |
| CAS-ID | 913088-80-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989949 |
| ChEBI ID | — |
| PubChem CID | 11962412 |
| DrugBank | DB06119 |
| UNII ID | P85X70RZWS (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GABRA4
GABRA4
GABRA6
GABRA6
Organism
Homo sapiens
Gene name
GABRA4
Gene synonyms
NCBI Gene ID
Protein name
gamma-aminobutyric acid receptor subunit alpha-4
Protein synonyms
GABA(A) receptor subunit alpha-4, GABA(A) receptor, alpha 4, gamma-aminobutyric acid (GABA) A receptor, alpha 4, gamma-aminobutyric acid A receptor alpha 4, gamma-aminobutyric acid type A receptor alpha4 subunit
Uniprot ID
Mouse ortholog
Gabra4 (14397)
gamma-aminobutyric acid receptor subunit alpha-4 (Q9D6F4)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 340 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,604 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use